Epirubicin

Head And Neck Cancer

Thomas Jefferson UniversityUNKNOWNPhase 3Active

BB

66/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 63/ 100
Competitive Position: 73/ 100

Competitive context

141 Active assets in the Head And Neck Cancer cohort.

Asset / Sponsor	Phase	Rating
Nepenthe Instituto Nacional de Cancer, Brazil	Phase 4	BB
Cis-Diamminedichloroplatinum Ii ImmunityBio, Inc.	Phase 3	BB
Lidocaine Instituto Nacional de Cancer, Brazil	Phase 3	BB
Carboplatin Rapa Therapeutics LLC	Phase 3	BB
Pembrolizumab Thomas Jefferson University	Phase 3	BB

View all 49 →

Same molecule, other indications

Epirubicin is also rated in:

estrogen-receptor negative breast cancerActive

BB

Indicative · Phase 2

71 / 100

progesterone-receptor negative breast cancerActive

BB

Indicative · Phase 2

71 / 100

inflammatory breast carcinomaActive

BB

Indicative · Phase 3

70 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.